Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Insider

QNCX

Quince Therapeutics Inc

May 17 • 04:00PM ET

0.9050

Dollar change -0.0149
Percentage change -1.62	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	25.33%	Shs Outstand	42.97M	Perf Week	-4.74%
Market Cap	39.11M	Forward P/E	-	EPS next Y	-	Insider Trans	1.56%	Shs Float	32.27M	Perf Month	-14.62%
Income	-30.28M	PEG	-	EPS next Q	-	Inst Own	16.37%	Short Float	6.11%	Perf Quarter	-29.30%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-17.73%	Short Ratio	25.40	Perf Half Y	1.69%
Book/sh	1.72	P/B	0.53	EPS next Y	-	ROA	-23.97%	Short Interest	1.97M	Perf Year	-43.08%
Cash/sh	1.57	P/C	0.58	EPS next 5Y	18.30%	ROE	-36.84%	52W Range	0.84 - 1.74	Perf YTD	-13.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.64%	ROI	-34.34%	52W High	-47.99%	Beta	1.18
Dividend TTM	-	Quick Ratio	7.16	Sales past 5Y	0.00%	Gross Margin	-	52W Low	7.74%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	7.16	EPS Y/Y TTM	38.03%	Oper. Margin	0.00%	RSI (14)	37.38	Volatility	6.59% 7.18%
Employees	32	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	12.00
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	24.17%	Payout	-	Rel Volume	2.93	Prev Close	0.92
Sales Surprise	-	EPS Surprise	-81.95%	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	77.64K	Price	0.90
SMA20	-8.36%	SMA50	-14.21%	SMA200	-19.58%	Trades		Volume	227,284	Change	-1.62%

May-13-24 01:53PM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference (Business Wire)
Apr-02-24 09:53AM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results (Business Wire)
07:00AM	Loading…
Feb-22-24 07:00AM	Quince Therapeutics Launches Scientific Advisory Board (Business Wire)
Feb-15-24 07:00AM	Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors (Business Wire)
Feb-07-24 04:05PM	Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-04-24 04:05PM	Quince Therapeutics to Participate at Investor Events in January 2024 (Business Wire)
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Oct-23-23 07:00AM	Quince Therapeutics Completes Acquisition of EryDel S.p.A. (Business Wire)
Sep-28-23 04:05PM	U.S. FDA Partial Clinical Hold Lifted on IND for EryDels Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia (Business Wire)
Sep-06-23 07:00AM	Quince Therapeutics Appoints Dr. Charles S. Ryan as President (Business Wire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:05PM	Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023 (Business Wire)
07:00AM	Loading…
Jul-24-23 07:00AM	Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity (Business Wire) -27.22%
Jul-13-23 08:00AM	Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +7.84%
Jun-06-23 08:00AM	Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value (ACCESSWIRE)
Apr-11-23 07:00AM	Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital (Business Wire)
Apr-06-23 04:05PM	Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor (Business Wire)
Apr-05-23 04:05PM	Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan (Business Wire) -6.70%
Mar-22-23 05:00AM	Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital (Business Wire)
Mar-21-23 08:00AM	Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +71.10%
Jan-30-23 04:05PM	Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023 (Business Wire) -7.41%
Jan-27-23 08:00AM	Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals (Business Wire) +33.66%
Nov-21-22 09:09AM	We Think Quince Therapeutics (NASDAQ:QNCX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-16-22 08:00AM	Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury (Business Wire) -6.83%
Sep-12-22 08:00AM	Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications (Business Wire)
Aug-30-22 04:05PM	Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures (Business Wire)
Aug-25-22 04:05PM	Quince Therapeutics to Present at Upcoming Scientific Meetings (Business Wire)
08:00AM	Loading…
Aug-04-22 08:00AM	Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022 (Business Wire)
Aug-01-22 08:00AM	Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name (Business Wire)

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thye Dirk	CHIEF EXECUTIVE OFFICER	Jan 16 '24	Option Exercise	0.79	240,530	190,791	689,441	Jan 17 04:48 PM
Lamond David	Director	Dec 14 '23	Buy	1.04	22,627	23,532	2,347,545	Dec 14 06:21 PM
Lamond David	Director	Dec 13 '23	Buy	1.00	22,627	22,627	2,324,918	Dec 14 06:21 PM
Lamond David	Director	Dec 12 '23	Buy	1.02	22,327	22,774	2,302,291	Dec 14 06:21 PM
Lamond David	Director	Dec 12 '23	Buy	1.00	300	300	2,279,964	Dec 14 06:21 PM
Lamond David	Director	Dec 07 '23	Buy	1.01	19,123	19,314	2,279,664	Dec 07 06:30 PM
Lamond David	Director	Dec 06 '23	Buy	1.02	19,123	19,505	2,260,541	Dec 07 06:30 PM
Lamond David	Director	Dec 05 '23	Buy	1.01	19,123	19,314	2,241,418	Dec 07 06:30 PM
Lamond David	Director	Dec 01 '23	Buy	0.94	14,378	13,515	2,222,295	Dec 01 01:38 PM
Lamond David	Director	Nov 30 '23	Buy	0.90	14,378	12,940	2,207,917	Dec 01 01:38 PM
Lamond David	Director	Nov 29 '23	Buy	0.98	14,378	14,090	2,193,539	Dec 01 01:38 PM
Lamond David	Director	Aug 31 '23	Buy	1.32	41,026	54,154	2,179,161	Aug 31 06:42 PM
Lamond David	Director	Aug 30 '23	Buy	1.31	41,026	53,744	2,138,135	Aug 31 06:42 PM
Lamond David	Director	Aug 17 '23	Buy	1.29	24,766	31,948	2,097,109	Aug 17 06:08 PM
Lamond David	Director	Aug 16 '23	Buy	1.29	117,348	151,379	2,072,343	Aug 17 06:08 PM
Lamond David	Director	Aug 15 '23	Buy	1.32	107,886	142,410	1,954,995	Aug 17 06:08 PM
Thye Dirk	Chief Executive Officer	Aug 10 '23	Buy	1.26	88,000	110,880	448,911	Aug 11 04:15 PM
Thye Dirk	Chief Executive Officer	Aug 08 '23	Buy	1.24	80,000	99,200	360,911	Aug 09 06:23 PM
Hannah Brendan	Chief Business Officer	Aug 08 '23	Buy	1.22	71,762	87,550	201,555	Aug 09 06:21 PM
McLoughlin Margaret	Director	Aug 08 '23	Buy	1.23	8,000	9,840	8,000	Aug 09 06:18 PM

QNCX

Quince Therapeutics Inc

Upgrade your FINVIZ experience